Laura Testa
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Cancer Risks and Factors
- Cancer Research top 10%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 40
- Cancer Treatment and Pharmacology 12
- Cancer Immunotherapy and Biomarkers 10
- HER2/EGFR in Cancer Research 6
-
- Advanced Breast Cancer Therapies 18
- Co-authors
- Javier Cortés (7 shared papers)Vassiliki Karantza (8 shared papers)Anthony Gonçalvès (8 shared papers)Nadia Harbeck (11 shared papers)Peter Schmid (5 shared papers)Fabrice André (6 shared papers)Stefania Zambelli (5 shared papers)Seock‐Ah Im (7 shared papers)
- Journals
- Journal of Clinical Oncology (9 papers)Annals of Oncology (7 papers)Cancer Research (6 papers)The Breast (4 papers)The Oncologist (2 papers)
- Partner nations
- BrazilUnited StatesSpain
In The Last Decade
Laura Testa
52 papers receiving 1.0k citations
Laura Testa's Hit Papers
Peers
Comparison fields: 5 of 90
- Oncology 676
- Cancer Research 162
- Immunology 159
- Pulmonary and Respiratory Medicine 172
- Epidemiology 68
Countries citing papers authored by Laura Testa
This map shows the geographic impact of Laura Testa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Testa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Testa more than expected).
Fields of papers citing papers by Laura Testa
This network shows the impact of papers produced by Laura Testa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Testa. The network helps show where Laura Testa may publish in the future.
Co-authors
The 25 scholars most cited alongside Laura Testa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 65 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 352 |
| 2 | 2012 | 113 | |
| 3 | 2019 | 98 | |
| 4 | 2019 | 85 | |
| 5 | 2020 | 51 | |
| 6 | 2020 | 49 | |
| 7 | 2013 | 33 | |
| 8 | 2018 | 32 | |
| 9 | 2021 | 28 | |
| 10 | 2013 | 21 | |
| 11 | 2024 | 19 | |
| 12 | 2022 | 16 | |
| 13 | 2024 | 15 | |
| 14 | 2019 | 14 | |
| 15 | 2022 | 11 | |
| 16 | 2024 | 10 | |
| 17 | 2020 | 9 | |
| 18 | 2023 | 8 | |
| 19 | 2024 | 8 | |
| 20 | 2014 | 6 |
About Laura Testa
Laura Testa is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Epidemiology and Cardiology and Cardiovascular Medicine, having authored 65 papers that have together received 1.1k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (18 papers), Cancer Treatment and Pharmacology (12 papers), Breast Cancer Treatment Studies (10 papers), Cancer Immunotherapy and Biomarkers (10 papers), HER2/EGFR in Cancer Research (6 papers), Chemotherapy-induced cardiotoxicity and mitigation (4 papers), Cancer Genomics and Diagnostics (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). The work is most often cited by research in Oncology (676 citations), Cancer Research (162 citations), Immunology (159 citations), Pulmonary and Respiratory Medicine (172 citations) and Epidemiology (68 citations). Laura Testa has collaborated with scholars based in Brazil, United States and Spain. Frequent co-authors include Javier Cortés, Vassiliki Karantza, Anthony Gonçalvès, Nadia Harbeck, Peter Schmid, Fabrice André, Stefania Zambelli, Seock‐Ah Im, Shoichiro Ohtani and Eric P. Winer. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, The Breast and The Oncologist.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.